Can CBD Cure Anxiety Disorders?
Anxiety disorder is a mental health condition that involves a feeling of insecurity and fear. People having serious anxiety symptoms suffer from panic attacks, intense situations where they feel insecure, and fear or terror....
Read More
Seven Emerging Job Opportunities in Weed
Got a bad case of the Mondays? Maybe a career shift is in order… Here are some emerging job opportunities in weed.
Read More
5 Qualities a Dispensary Budtender Needs to Have
As world markets continue to be affected by the Coronavirus (COVID-19), corporations in all...
Read More
FEATURED NEWS
Epidiolex in the U.S. yielded Q2 net sales of $68.4 million. The company featured the value that cannabinoid-based patents provide in the innovative and ever-growing cannabis industry. The company reported financial results for the second quarter ended June 30, 2019.GW Pharmaceuticals plc Reports Financial Results and Operational Progress for the Second Quarter Ended June 30, 2019
AXIM® Biotechnologies Featured in Bloomberg Law for Robust Cannabinoid-Based Patent Portfolio
Zynerba Pharmaceuticals Reports Second Quarter 2019 Financial Results and Operational Highlights
LATEST STOCK NEWS
Founder and Chief Executive Officer Ben Kovler will participate in a fireside chat with Cowen Managing Director and Senior Research Analyst Vivien Azer. Cara Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing new chemical entities. The Shareholder Letter was cascaded earlier today and can be found on WeedMD’s website here.Green Thumb Industries (GTI) Announces Conference Participation for December 2019
Cara Therapeutics Announces Positive Topline Data From Phase 2 Trial of Oral KORSUVA™ in Chronic Kidney Disease Patients with Moderate-to-Severe Pruritus
WeedMD Posts Open Letter to Shareholders
GET LISTED
